, Volume 66, Issue 9, pp 1179–1189

Novel Treatment Options for Inflammatory Bowel Disease

Targeting α4 Integrin
  • Francesco Lanzarotto
  • Marta Carpani
  • Rakesh Chaudhary
  • Subrata Ghosh
Leading Article


The aetiology of inflammatory bowel disease (IBD) is complex and many aspects still remain unclear. However, significant progress has been made in understanding the pathogenesis of chronic inflammation in the intestine, and new insights have been gained recently. A better understanding of the immunopathology of IBD has led to the development of novel biological agents to target crucial molecules and processes in the inflammatory cascade. The development of novel therapies in the management of IBD has moved from empirical to scientific rational translation from bench to bedside.

Lymphocyte infiltration into the intestinal tract in Crohn’s disease (CD) is mediated by interaction between α4 integrin expressed on lymphocytes and its specific ligand mucosal vascular addressin cell adhesion molecule-1, expressed on the endothelial cells of the microvasculature in the inflamed intestinal tract. Development of monoclonal antibodies against α4 integrin permitted the targeting of lymphocyte trafficking into the intestine as a novel therapeutic intervention. Natalizumab, a recombinant humanised monoclonal antibody against α4 integrin, was effective in CD in a phase II randomised controlled trial. The highest response rate and remission rate were 71% and 44%, respectively, at 6 weeks after two infusions of natalizumab 3mg administered 4 weeks apart. Natalizumab was well tolerated in this trial. The phase III trial results are encouraging, although the primary efficacy endpoint of response at week 10 was not achieved. The maintenance of response and remission trial, ENACT (Evaluation of Natalizumab as Continuous Therapy)-2, has reported impressive efficacy in maintaining response and remission in those who responded in the initial induction of remission (ENACT-1) trial. This was associated with an improvement in quality-of-life parameters. A second humanised monoclonal antibody, MLN-02 (LDP-02), developed against α4β7 has also shown evidence of efficacy in ulcerative colitis and CD.

Although the clinical trials showed that inhibition of α4 integrin was well tolerated, use of natalizumab in multiple sclerosis and CD has raised serious concerns about the association with progressive multifocal leukoencephalopathy (PML) in a small number of patients, and the drug has been withdrawn from the market pending further safety evaluation. PML is caused by polyoma JC virus infection, is progressive and generally fatal, and is recognised to occur in patients with severe immunosuppression. Initial safety evaluation suggests that PML is very rare, despite its occurrence in one patient with CD receiving open-label natalizumab treatment.


  1. 1.
    Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521–33PubMedCrossRefGoogle Scholar
  2. 2.
    Arnott IDR, Watts D, Ghosh S. Is clinical remission the optimum therapeutic goal in the treatment of Crohn’s disease? Aliment Pharmacol Ther 2002; 16: 857–60PubMedCrossRefGoogle Scholar
  3. 3.
    Ghosh S. Anti-TNF strategies in Crohn’s disease. In: Jewell D, editor. Inflammatory bowel disease: crossroads between microbes, epithelium and immune systems. Novartis Foundation Symposium 263. Chichester: Wiley, 2004Google Scholar
  4. 4.
    Springer TA. Traffic signals of lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301–14PubMedCrossRefGoogle Scholar
  5. 5.
    Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60–6PubMedCrossRefGoogle Scholar
  6. 6.
    Meenan J, Mevissen M, Monajemi H, et al. Mechanisms underlying neutrophil adhesion to apical epithelial membranes. Gut 1996; 38: 201–5PubMedCrossRefGoogle Scholar
  7. 7.
    Binion DG, West GA, Volk EE, et al. Acquired increase in leukocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998; 352: 1742–6PubMedCrossRefGoogle Scholar
  8. 8.
    Koizumi M, King N, Lobb R, et al. Expression of vascular adhesion molecule in inflammatory bowel disease. Gastroenterology 1992; 103: 840–7PubMedGoogle Scholar
  9. 9.
    Kuhlman P, May VT, Lollo BA, et al. The accessory function of murine intercellular adhesion molecule-1 in T-lymphocyte activation. J Immunol 1991; 146: 1773–82PubMedGoogle Scholar
  10. 10.
    Ghosh S. Recognition and management of inflammatory bowel disease. J R Coll Physicians Edinb 2005; 35: 50–4Google Scholar
  11. 11.
    D’Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667–71PubMedCrossRefGoogle Scholar
  12. 12.
    D’Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histologic healing with infliximab anti-tumour necrosis factor antibodies in Crohn’s disease: a European multicentre trial. Gastroenterology 1999; 116: 1029–34PubMedCrossRefGoogle Scholar
  13. 13.
    Leger OJ, Yednock TA, Tanner L, et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997; 8: 3–16PubMedGoogle Scholar
  14. 14.
    Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002; 16: 699–705PubMedCrossRefGoogle Scholar
  15. 15.
    Gordon FH, Lai CWY, Hamilton MI, et al. A randomised placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn’s disease. Gastroenterology 2001; 121: 268–74PubMedCrossRefGoogle Scholar
  16. 16.
    Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 1993; 92: 372–80PubMedCrossRefGoogle Scholar
  17. 17.
    Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to gut-homing integrin α4β7. Gastroenterology 1996; 111: 1373–80PubMedCrossRefGoogle Scholar
  18. 18.
    Ghosh S, Goldin E, Gordon F, et al. Natalizumab for active Crohn’s disease. N Engl J Med 2003; 348: 24–32PubMedCrossRefGoogle Scholar
  19. 19.
    Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005; 353: 1912–5PubMedCrossRefGoogle Scholar
  20. 20.
    Targan SR, Feagan B, Fedorak R, et al. Natalizumab induces sustained response and remission in patients with active Crohn’s disease: results from the ENCORE trial [abstract no. 747]. Gastroenterology 2006; 130 Suppl. 2: 180Google Scholar
  21. 21.
    Ghosh S, Allison M, Nwokolo C, et al. Maintenance therapy with natalizumab improves quality of life in patients with Crohn’s disease [abstract]. Gut 2005; 54 Suppl. 2: A23CrossRefGoogle Scholar
  22. 22.
    Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369–74PubMedCrossRefGoogle Scholar
  23. 23.
    Langer-Gould A, Atlas SW, Bollen AW, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375–81PubMedCrossRefGoogle Scholar
  24. 24.
    Van Assche G, Ranst MV, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353: 362–8PubMedCrossRefGoogle Scholar
  25. 25.
    Shitrit D, Lev N, Bar-Gil SA, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005; 17: 658–65PubMedCrossRefGoogle Scholar
  26. 26.
    Sandborn W, Targan S. A safety evaluation for progressive multifocal leukoencephalopathy (PML) in greater than 3500 patients with Crohn’s disease (CD), multiple sclerosis (MS), and rheumatoid arthritis (RA) previously treated with natalizumab in clinical trials. Gastroenterology 2006; 130 Suppl. 2: A72Google Scholar
  27. 27.
    Yacychyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease. Gastroenterology 1998; 114: 1133–42CrossRefGoogle Scholar
  28. 28.
    Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn’s disease. Gastroenterology 2001; 120: 1339–46PubMedCrossRefGoogle Scholar
  29. 29.
    Van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled double-blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004; 53: 1646–51PubMedCrossRefGoogle Scholar
  30. 30.
    Feagan BG, McDonald J, Greenberg G, et al. An ascending dose trial of a humanized α4β7 antibody in ulcerative colitis (UC) [abstract]. Gastroenterology 2000; 118: A874CrossRefGoogle Scholar
  31. 31.
    Feagan BG, Greenberg G, Wild G, et al. A randomized controlled trial of a humanized α4β7 antibody in ulcerative colitis [abstract]. Gastroenterology 2003; 125: A606Google Scholar
  32. 32.
    Feagan BG, Greenberg G, Wild G, et al. Efficacy and safety of a humanized α4β7 antibody in active Crohn’s disease (CD). Gastroenterology 2003; 124 Suppl. 1: A25–6CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Francesco Lanzarotto
    • 1
  • Marta Carpani
    • 1
  • Rakesh Chaudhary
    • 1
  • Subrata Ghosh
    • 1
  1. 1.Department of GastroenterologyImperial College London, Hammersmith HospitalLondonUK

Personalised recommendations